Tiziana Life Sciences (TLSA) has filed
a provisional patent application on the combination of
nanoparticle-Actinomycin D (NP-ACT D) with anti-interleukin-6 receptor
monoclonal antibody (anti-IL-6R) as a potential therapy for management
of COVID-19 disease.
The underlying invention concepts are based on the
hypothesis that a combination of an antiviral drug controlling
proliferation of COVID-19, with an anti-inflammatory agent (e.g., anti-IL-6R) suppressing a possible ‘Cytokine Storm’ may provide immediate relief to severe cases of COVID-19 patients.
https://seekingalpha.com/news/3564640-tiziana-life-files-new-patent-application-for-treatment-of-coronaviruses
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.